A few studies which included HF post-STEMI as a clinical endpoint, had several limitations such as the use of composite endpoints, CRP measurement only at hospital admission for STEMI, lack of data on echocardiographic outcomes, no measurements of other biomarkers like BNP, and the use of guideline-based therapies only in portion of enrolled patients [18,19,39]. Here, NPPB is linked to hydrops fetalis.